Clusterin

CLU
Identifiers
Aliases	CLU, AAG4, APO-J, APOJ, CLI, CLU1, CLU2, KUB1, NA1/NA2, SGP-2, SGP2, SP-40, TRPM-2, TRPM2, clusterin
External IDs	OMIM: 185430 MGI: 88423 HomoloGene: 1382 GeneCards: CLU
Gene location (Human) Chr. Chromosome 8 (human) Band 8p21.1 Start 27,596,917 bp End 27,614,700 bp
Gene location (Mouse) Chr. Chromosome 14 (mouse) Band 14 D1|14 34.36 cM Start 66,205,932 bp End 66,218,996 bp
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in external globus pallidus Achilles tendon palpebral conjunctiva optic nerve Brodmann area 10 right uterine tube middle frontal gyrus Brodmann area 9 olfactory bulb caput epididymis Top expressed in iris ciliary body habenula paraventricular nucleus of hypothalamus dorsomedial hypothalamic nucleus dorsal tegmental nucleus subiculum ventral tegmental area molar arcuate nucleus More reference expression data BioGPS n/a
Gene ontology Molecular function chaperone binding misfolded protein binding ATPase activity protein binding ubiquitin protein ligase binding Cellular component cytoplasm apical dendrite cytosol Golgi apparatus blood microparticle mitochondrial membrane membrane extracellular matrix neurofibrillary tangle chromaffin granule spherical high-density lipoprotein particle extracellular region cell surface intracellular membrane-bounded organelle mitochondrion endoplasmic reticulum extracellular exosome platelet alpha granule lumen nucleus cytoplasmic vesicle intracellular anatomical structure perinuclear region of cytoplasm extracellular space Biological process apoptotic process central nervous system myelin maintenance negative regulation of protein homooligomerization response to misfolded protein chaperone-mediated protein complex assembly positive regulation of tau-protein kinase activity lipid metabolism immune system process negative regulation of amyloid-beta formation positive regulation of nitric oxide biosynthetic process complement activation response to virus protein stabilization platelet degranulation positive regulation of neuron death negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage positive regulation of neurofibrillary tangle assembly microglial cell activation protein import intrinsic apoptotic signaling pathway positive regulation of amyloid-beta formation regulation of neuronal signal transduction microglial cell proliferation positive regulation of NF-kappaB transcription factor activity positive regulation of ubiquitin-dependent protein catabolic process cell morphogenesis regulation of neuron death complement activation, classical pathway positive regulation of tumor necrosis factor production positive regulation of apoptotic process regulation of amyloid-beta clearance innate immune response positive regulation of intrinsic apoptotic signaling pathway positive regulation of proteasomal ubiquitin-dependent protein catabolic process release of cytochrome c from mitochondria reverse cholesterol transport chaperone-mediated protein folding antimicrobial humoral response cell death Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 1191 12759 Ensembl ENSG00000120885 ENSMUSG00000022037 UniProt P10909 Q06890 RefSeq (mRNA) NM_001831 NM_013492 RefSeq (protein) NP_001822 NP_038520 Location (UCSC) Chr 8: 27.6 – 27.61 Mb Chr 14: 66.21 – 66.22 Mb PubMed search
Wikidata
View/Edit Human View/Edit Mouse

Clusterin (apolipoprotein J) is a 75-80 kDa disulfide-linked heterodimeric protein associated with the clearance of cellular debris and apoptosis. In humans, clusterin is encoded by the CLU gene on chromosome 8. CLU is a molecular chaperone responsible for aiding protein folding of secreted proteins, and its three isoforms have been differentially implicated in pro- or antiapoptotic processes. Through this function, CLU is involved in many diseases related to oxidative stress, including neurodegenerative diseases, cancers, inflammatory diseases, and aging.

Structure

The CLU gene contains nine exons and expresses three isoforms alternatively-spliced at the first exon. The encoded protein isoforms all localize to different subcellular compartments: one isoform localizes to the nucleus; a second isoform localizes to the cytoplasm; and the third is secreted from the cell. They also perform opposing functions: the nuclear CLU binds Ku70 to release BAX and induce apoptosis, whereas the cytosolic and secretory isoforms inhibit apoptosis. The nuclear isoform encodes a 49 kDa protein, while the secretory isoform, which is the main gene transcript, encodes a 75–80 kDa protein after maturation (glycosylation, secretion, and dimerization). The mature protein is a 449-residue, heterodimeric, disulfide-linked glycoprotein composed of two subunits of ~34-40 kDa α- and β-chains.

Function

Clusterin was first identified in ram rete testis fluid where it showed signs of clustering with rat sertoli cells and erythrocytes, hence its name.

CLU is a member of the small heat shock protein family and, thus, a molecular chaperone. Unlike most other chaperone proteins, which aid intracellular proteins, CLU is a Golgi chaperone that facilitates the folding of secreted proteins in an ATP-independent way. The gene is highly conserved in species, and the protein is widely distributed in many tissues and organs, where it participates in a number of biological processes, including lipid transport, membrane recycling, cell adhesion, programmed cell death, and complement-mediated cell lysis. Overexpression of the secretory CLU isoform protects the cell from apoptosis induced by cellular stress, such as chemotherapy, radiotherapy, or androgen/estrogen depletion. CLU promotes cell survival by a number of means, including inhibition of BAX on the mitochondrial membrane, activation of the phosphatidylinositol 3-kinase/protein kinase B pathway, modulation of extracellularular signal-regulated kinase (ERK) 1/2 signaling and matrix metallopeptidase-9 expression, promotion of angiogenesis, and mediation of the nuclear factor kappa B (NF-κB) pathway. Meanwhile, its downregulation allows for p53 activation, which then skews the proapoptotic:antiapoptotic ratio of present Bcl-2 family members, resulting in mitochondrial dysfunction and cell death. p53 may also transcriptionally repress secretory CLU to further promote the proapoptotic cascade.

Clinical associations

Two independent genome-wide association studies found a statistical association between a SNP within the clusterin gene and the risk of having Alzheimer's disease. Further studies have suggested that people who already have Alzheimer's disease have more clusterin in their blood, and that clusterin levels in blood correlate with faster cognitive decline in individuals with Alzheimer's disease, but have not found that clusterin levels predicted the onset of Alzheimer's disease. In addition to Alzheimer's disease, CLU is involved in other neurodegenerative diseases such as Huntington disease.

CLU may promote tumorigenesis by facilitating BAX-KLU70 binding and, consequently, preventing BAX from localizing to the outer mitochondrial membrane to stimulate cell death. In clear cell renal cell carcinoma, CLU functions to regulate ERK 1/2 signaling and matrix metallopeptidase-9 expression to promote tumor cell migration, invasion, and metastasis. In epithelial ovarian cancer, CLU has been observed to promote angiogenesis and chemoresistance. Other pathways CLU participates in to downplay apoptosis in tumor cells include the PI3K/AKT/mTOR pathway and NF-κB pathway. Unlike most other cancers, which feature upregulated CLU levels to enhance tumor cell survival, testicular seminoma features downregulated CLU levels, allowing for increased sensitivity to chemotherapy treatments. Other cancers CLU has been implicated in include breast cancer, pancreatic cancer, hepatocellular carcinoma, and melanoma.

As evident by its key roles in cancer development, CLU can serve as a therapeutic target for fighting tumor growth and chemoresistance. Studies revealed that inhibition of CLU resulted in increased effectiveness of chemotherapeutic agents to kill tumor cells. In particular, custirsen, an antisense oligonucleotide that blocks the CLU mRNA transcript, enhanced heat-shock protein 90 (HSP90) inhibitor activity by suppressing the heat-shock response in castrate-resistant prostate cancer, and is currently in phase III trials.

CLU activity is also involved in infectious diseases, such as hepatitis C. CLU is induced by the stress of hepatitis C viral infection, which disrupts glucose regulation. The chaperone protein then aids hepatitis C viral assembly by stabilizing its core and NS5A units. CLU expression in the kidney also plays a role in renal diseases, such as nephropathic cystinosis, which is a major cause of Fanconi syndrome. In addition to the above diseases, CLU has been linked to other conditions resulting from oxidative damage, including aging, glomerulonephritis, atherosclerosis, and myocardial infarction.

Interactions

CLU has been shown to interact with Ku70.

Further reading

External links

• Clusterin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Apolipoproteins and Applied Research